📊 ATXI Key Takeaways
Is Avenue Therapeutics, Inc.. (ATXI) a Good Investment?
Avenue Therapeutics is a pre-revenue pharmaceutical company with severe operational losses and minimal commercialization progress. With only $1.4M in revenue against $2.3M in operating losses and rapidly depleting cash despite solid cash position, the company faces critical funding pressure and lacks evidence of viable product traction.
Avenue Therapeutics shows very weak core fundamentals, with minimal revenue, deeply negative operating and net margins, and continued losses despite only marginal year-over-year net income improvement. While the balance sheet is currently supported by cash and no long-term debt, the business appears dependent on its cash reserves rather than durable operating performance, which makes growth quality and financial sustainability poor.
Why Buy Avenue Therapeutics, Inc.. Stock? ATXI Key Strengths
- Maintains positive cash position of $3.7M providing near-term runway
- Zero long-term debt indicating no financial leverage burden
- Current ratio of 2.78x demonstrates adequate short-term liquidity
- Cash and equivalents of $3.71M provide near-term liquidity support
- No meaningful long-term debt reduces balance sheet leverage risk
- Current and quick ratios of 2.78x indicate adequate short-term solvency
ATXI Stock Risks: Avenue Therapeutics, Inc.. Investment Risks
- Operating margin of -166% and net margin of -157% indicate unsustainable unit economics
- Negative free cash flow of -979K annually will exhaust cash reserves within 3-4 years at current burn rate
- Revenue of only $1.4M against operating losses suggests early-stage commercialization failure or product market fit issues
- Negative ROE of -61.8% and ROA of -59.1% show destruction of shareholder capital
- Single Form 4 filing in 90 days provides limited visibility into insider confidence
- Operating margin of -166.0% and net margin of -156.7% indicate an unprofitable and unsustainable business model
- Free cash flow and operating cash flow are negative, implying ongoing cash burn
- Asset base is very small and largely concentrated in cash, limiting operational resilience if losses continue
Key Metrics to Watch
- Quarterly revenue growth trajectory and product commercialization milestones
- Monthly cash burn rate and runway remaining before funding need
- Operating expense structure and path to break-even timing
- Quarterly operating cash burn relative to cash balance
- Revenue scale-up and improvement in operating margin
Avenue Therapeutics, Inc.. (ATXI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.78x current ratio provides a solid financial cushion.
ATXI Profit Margin, ROE & Profitability Analysis
ATXI vs Healthcare Sector: How Avenue Therapeutics, Inc.. Compares
How Avenue Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Avenue Therapeutics, Inc.. Stock Overvalued? ATXI Valuation Analysis 2026
Based on fundamental analysis, Avenue Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Avenue Therapeutics, Inc.. Balance Sheet: ATXI Debt, Cash & Liquidity
ATXI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Avenue Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.31 indicates the company is currently unprofitable.
ATXI Revenue Growth, EPS Growth & YoY Performance
ATXI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$683.0K | $-0.21 |
| Q2 2025 | N/A | $335.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Avenue Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
ATXI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Avenue Therapeutics, Inc.. (CIK: 0001644963)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATXI
What is the AI rating for ATXI?
Avenue Therapeutics, Inc.. (ATXI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATXI's key strengths?
Claude: Maintains positive cash position of $3.7M providing near-term runway. Zero long-term debt indicating no financial leverage burden. ChatGPT: Cash and equivalents of $3.71M provide near-term liquidity support. No meaningful long-term debt reduces balance sheet leverage risk.
What are the risks of investing in ATXI?
Claude: Operating margin of -166% and net margin of -157% indicate unsustainable unit economics. Negative free cash flow of -979K annually will exhaust cash reserves within 3-4 years at current burn rate. ChatGPT: Operating margin of -166.0% and net margin of -156.7% indicate an unprofitable and unsustainable business model. Free cash flow and operating cash flow are negative, implying ongoing cash burn.
What is ATXI's revenue and growth?
Avenue Therapeutics, Inc.. reported revenue of $1.4M.
Does ATXI pay dividends?
Avenue Therapeutics, Inc.. does not currently pay dividends.
Where can I find ATXI SEC filings?
Official SEC filings for Avenue Therapeutics, Inc.. (CIK: 0001644963) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATXI's EPS?
Avenue Therapeutics, Inc.. has a diluted EPS of $-1.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ATXI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Avenue Therapeutics, Inc.. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ATXI stock overvalued or undervalued?
Valuation metrics for ATXI: ROE of -61.8% (sector avg: 15%), net margin of -156.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ATXI stock in 2026?
Our dual AI analysis gives Avenue Therapeutics, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ATXI's free cash flow?
Avenue Therapeutics, Inc..'s operating cash flow is $-979.0K, with capital expenditures of N/A. FCF margin is -69.7%.
How does ATXI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -156.7% (avg: 12%), ROE -61.8% (avg: 15%), current ratio 2.78 (avg: 2).